GOLDIS - NOTICE OF BOOK CLOSURE

GOLDIS BERHAD

LISTING'S CIRCULAR NO. L/Q : 69971 OF 2014


Distribution of three (3) treasury shares for every one hundred (100) existing ordinary shares of RM1.00 each ("Share Dividend"). Fractions of treasury shares are to be disregarded.

Kindly be advised of the following :

1) The above Company's securities will be traded and quoted [ "Ex - Dividend" ]
as from : [ 12 March 2014 ]

2) The last date of lodgement : [ 14 March 2014 ]

3) Date Payable : [ 27 March 2014 ]

Announcement Info
Company Name GOLDIS BERHAD
Stock Name GOLDIS
Date Announced 3 Mar 2014
Category Listing Circular
Reference No RN-140303-31288

Normal lah up and down. Investor sell so that can move the fund to develop country

Up and down. But do not catch the falling knife

Result out

Result out

Bonia, dksh , Goldis , igb

I believe one day will be a gold

3.84 high. Cls is 3.70

Not yet announce result. Some one want to ask us sell

To oil and gas, transport and property development nothing else. Low margin

For 2.80

Just a normal manufature

Land issue

Dksh -next trade Alex say better take profit.

I think the price is fair unless the earning really grow beyond 7% to be conservative.

Wait below 4.00

Will go down further. Everybody is selling

125%

Than better buy the hovid warrant

No research firm write anything on dksh. Funny

Will Dksh keep up again for 2014.

Still dksh

Buy again

Dksh

Buy today.

Dksh economy bad still people need the service. Bonia is for rich people. Ghlsys when people getting more cost cations there will he for paperless. Is the way to go forward

DKSH provides clinical trial logistics services to Nordic Bioscience in Hong Kong

12.12.2013 | DKSH, the leading Market Expansion Services provider with a focus on Asia, has signed an agreement with Nordic Bioscience, an international biotech organization, to offer clinical trial logistics services in Hong Kong.

Hong Kong, December 12, 2013 – DKSH’s Business Unit Healthcare, the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia, has signed an agreement with Nordic Bioscience to provide clinical trial logistics services in Hong Kong. Under the agreement, DKSH is responsible for the importation of investigational products, products storage, delivery, return and destruction.

“Hong Kong has excellent infrastructure in terms of transportation, workforce and legal framework for conducting clinical trials. What we need is to find a partner which can offer clinical trial logistics services in a safe manner with high security and reliability,” said Jeppe Ragnar Andersen, Head of Clinical Development, Nordic Bioscience. “We are happy to work with DKSH Hong Kong. Its specialized clinical trial team should help us ensure that the logistics of our trials are managed with the expertise and quality we demand.”

“Our company is certified to comply with international standards (ISO, GMP, GDP), ensuring our clients peace of mind on storage and service execution. Our distribution center environment together with our talented team offer the best possible solution for clinical trial logistics services in Hong Kong,” said Richard Holloway, Vice President, DKSH Healthcare, Hong Kong. “The number of clinical trials in Asia has been increasing steadily. We are seeing rising demands and referrals from clinical research organizations on clinical trial logistics services in Hong Kong. This value-added service poised great business potential in addition to our traditional offerings.”

The new partnership will further strengthen DKSH’s market position in healthcare in Hong Kong while contributing incrementally to the Group’s overall profitability over time.

About Nordic Bioscience

Nordic Bioscience is an international biotech organization with research facilities in Copenhagen, Denmark, and in Beijing, China. The company comprises three divisions: Biomarkers & Research, Clinical Develop-ment, and the Laboratory. It is a group with the capacity and specialist expertise to develop protocols for, manage, and support studies ranging from those in early preclinical phases to the pivotal phase IIIs required for marketing authorization.

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term “Market Expansion Services” suggests, DKSH helps other companies and brands to grow their business in new or existing markets.

Publicly listed on the SIX Swiss Exchange since March 2012, DKSH is a global company headquartered in Zurich. With 680 business locations in 35 countries – 660 of them in Asia – and 25,900 specialized staff, DKSH generated net sales of CHF 8.8 billion in 2012.

DKSH Business Unit Healthcare is the leading Market Expansion Ser-vices provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration and market entry studies as well as importation, customs clearance, marketing and sales to physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include ethical pharmaceuticals, consumer health, over-the-counter (OTC), as well as medical devices.

With 150 business locations in 13 countries and around 8,270 specialized staff, Business Unit Healthcare serves over 160,000 customers and gen-erated net sales of around CHF 3.7 billion in 2012.

7.96

Buy also

Even above 2.50

Tired already. May even drop to 0.42

Wait until it happen than will run

Buy more again

I will wait until 2.70

Go down buy some more

Buy again and keep for 2years

Buy dksh at 2.02. Sell some and still keep some

Something wrong.

See can go up further

Already send the offer. Due dec 10

Price in

Sooner or later will come down

Igb cancel treasury share

If continue to be like this than maybe corporate announcement.

Wait and see it down

Move again

Yeap correct. So at least rm
8.00

Going down

See can break 0.915

Valuation too expensive